SCHEMBL5010620

SCHEMBL5010620

Cc1ccc(C)c(-n2nc(-c3ccccc3)cc2Nc2ccccc2C(=O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.51
LMNA P02545 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
GAA P10253 2/20 0.51
MAPK1 P28482 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
TP53 P04637 1/20 0.49
ALDH1A1 P00352 1/20 0.48
GFER P55789 1/20 0.47
GRM5 P41594 2/20 0.47
POLB P06746 2/20 0.45
KDM4E B2RXH2 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
FABP4 P15090 1/20 0.44
RAB9A P51151 1/20 0.44
TAS2R14 Q9NYV8 1/20 0.44
ADORA1 P30542 1/20 0.43
FTO Q9C0B1 1/20 0.43
DHODH Q02127 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5011993 0.90 ADORA1 (0.52) MAPTLMNAMEN1KMT2AGAA
SCHEMBL5008441 0.89 MAPT (0.47) MAPTLMNAMEN1KMT2AGAA
SCHEMBL5007754 0.89 ADORA1 (0.52) MAPTLMNAMEN1KMT2AGAA
SCHEMBL5011998 0.88 MAPT (0.59) MAPTLMNAMEN1KMT2AGAA
SCHEMBL5007715 0.87 MAPT (0.43) MAPTLMNAMEN1KMT2AGAA
SCHEMBL5008775 0.87 ADORA1 (0.55) MAPTLMNAMEN1KMT2AGAA
SCHEMBL3859778 0.85 LMNA (0.50) MAPTLMNAMEN1KMT2AGAA
SCHEMBL5007721 0.85 MAPK14 (0.55) MAPTGFERTAS2R14
SCHEMBL5005236 0.84 ADORA1 (0.56) MAPTLMNAMEN1KMT2AGAA
SCHEMBL5011976 0.84 ADORA1 (0.49) MAPTLMNAMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2008-03-13 US disclosed
US-7265144-B2 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes IAPP, GLP1R, GPR119 MAPT 2420/4885LMNA 3247/4885MEN1 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.